Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis
| dc.contributor.author | Botzoris, V. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:05:29Z | |
| dc.date.available | 2015-11-24T19:05:29Z | |
| dc.identifier.issn | 1778-7254 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20201 | |
| dc.rights | Default Licence | - |
| dc.subject | Calcium Channel Blockers/therapeutic use | en |
| dc.subject | Cardiovascular Agents/*therapeutic use | en |
| dc.subject | Enzyme Inhibitors/therapeutic use | en |
| dc.subject | Fingers | en |
| dc.subject | Humans | en |
| dc.subject | Phosphodiesterase 5 Inhibitors/therapeutic use | en |
| dc.subject | Prostaglandins I/therapeutic use | en |
| dc.subject | Raynaud Disease/*drug therapy/etiology/physiopathology | en |
| dc.subject | Receptors, Endothelin/antagonists & inhibitors | en |
| dc.subject | Scleroderma, Systemic/complications/*drug therapy/physiopathology | en |
| dc.subject | Skin Ulcer/*drug therapy/etiology/physiopathology | en |
| dc.subject | Sulfonamides/therapeutic use | en |
| dc.subject | Vasodilator Agents/therapeutic use | en |
| dc.title | Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis | en |
| heal.abstract | Raynaud's phenomenon (RP) and digital ulcers (DU) are the clinical manifestations of vasculopathy in systemic sclerosis. Both interfere with hand function and hold the possibility of severe complications, thus adversely influencing patients' quality of life. Managing RP and DU is often a challenge for the treating physician, who has to establish a treatment plan based upon knowledge of the current therapeutic options. The first step is to differentiate primary from secondary RP, where combining history and physical examination with diagnostic modalities, such as nailfold capillaroscopy, aids in reaching the correct diagnosis. Next a wide range of treatment options is offered nowadays, starting from first-line agents, as calcium channel blockers, to the more targeted-ones, like endothelin receptor antagonists. Research and clinical experience with each agent are reviewed in the text, as well as the combinations that more recently gain field in the treatment of DU. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1016/j.jbspin.2010.11.005 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21183379 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S1297319X10002952/1-s2.0-S1297319X10002952-main.pdf?_tid=b0faf6b6ec463f04ba8447959742c272&acdnat=1333523578_cf392e728e0fb0fb8ec91bc0b6ebc6d6 | - |
| heal.journalName | Joint Bone Spine | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2011 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: